Tempus AI Inc (NASDAQ: TEM) shares climbed 5.09% to $70.04 on Friday, extending gains from Thursday’s premarket rally. The move follows continued investor digestion of positive Phase 3 clinical trial results from Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) for a personalized mRNA cancer vaccine.

The rally underscores the strategic value of Tempus AI’s pending $1.5 billion acquisition of Personalis Inc. Investors are linking the clinical success directly to Personalis’s sequencing platform, which is critical for manufacturing the custom vaccine doses used in the trial.

Clinical Trial Milestone

The catalyst remains the INTerpath-001 study results announced earlier in the week. The trial evaluated intismeran autogene, a customized mRNA-based individualized neoantigen therapy, in combination with Keytruda. The combination significantly improved recurrence-free survival in patients with resected melanoma.

This result marks the first successful Phase 3 readout for a customized mRNA-based cancer treatment. For Moderna, it validates its platform beyond pandemic-era origins. For Tempus AI, it confirms the commercial and technological relevance of the assets it is acquiring from Personalis.

The Personalis Connection

Moderna relies on Personalis’s sequencing platform to analyze patient tumor tissue and identify specific neoantigens required for manufacturing custom vaccine doses. This technological dependency makes the clinical success highly material for Tempus AI.

Tempus AI previously partnered with Personalis to commercialize minimal residual disease tests. By acquiring Personalis for $1.5 billion, Tempus inherits the critical sequencing infrastructure supporting Moderna’s therapeutic program as it achieves this major clinical milestone.

Tempus CEO Eric Lefkofsky highlighted the connection on social media Wednesday, congratulating Moderna and Merck while noting Tempus’s pride in supporting the breakthrough program.

Technical Analysis

At $70.04, Tempus AI is trading significantly above its trend gauges. The stock is up approximately 33% above its 20-day simple moving average (SMA) of $51.08 and 19.7% above its 200-day SMA of $56.75.

The Relative Strength Index (RSI) stands at 71.53, placing the stock in overbought territory. This typically signals that the move is stretched and upside may become harder to sustain without a reset. The broader technical picture remains mixed, with the 50-day SMA remaining below the 200-day SMA following a death cross in January.

Traders may watch $76.50 as near-term resistance where rebounds can stall. Meanwhile, $61.50 serves as key support, defining whether any pullback stays controlled.

What the Numbers Show

The divergence between Tempus AI’s technical indicators and its price action highlights strong fundamental validation overriding technical headwinds. While the RSI of 71.53 suggests overbought conditions and the stock trades well above its 20-day SMA ($51.08), the price has surged to $70.04. This indicates that investors are prioritizing the strategic utility of the Personalis acquisition—validated by the blockbuster oncology trial—over short-term momentum risks.

Tempus AI Inc. (NASDAQ: TEM) shares surged over 11% on Friday, significantly outperforming broader market indices including the Nasdaq Composite, which rose 0.86%, and the S&P 500, which gained 0.47%. The stock’s sharp advance also eclipsed the Healthcare sector’s modest 0.3% gain, reflecting investor enthusiasm for artificial intelligence applications in healthcare technology.

The primary catalyst for Tempus AI’s price movement was a broader sector-wide rally triggered by stellar earnings and guidance from industry peers, notably Doximity Inc. (NYSE: DOCS). Doximity reported fiscal first-quarter revenue of $156.6 million, beating consensus analyst estimates of $151.7 million. During the earnings call, Doximity CEO Jeff Tangney stated that AI is "up-leveling our business across the board" and noted that the market opportunity unlocked by AI "has been a real surprise and upside for us."

Strategic Collaboration with CellCarta

Adding to the positive momentum, Tempus AI announced a strategic collaboration with CellCarta on Thursday, August 6. Under the agreement, CellCarta added Tempus to its CDx Commercialization Lab Network as its second commercial laboratory partner. This partnership aims to support oncology companion diagnostics offerings to biopharma sponsors, expanding Tempus’s reach in the diagnostic space.

Technical Analysis and Key Levels

From a technical perspective, Tempus AI shares were trading at $50.95 at the time of publication, representing a 10.49% increase. The stock is currently trading approximately 5% above its 20-day Simple Moving Average (SMA) of $48.15, signaling a shift in near-term trend direction. However, longer-term pressure remains evident as the stock trades about 13% below its 200-day SMA of $58.31.

The Relative Strength Index (RSI) stands at 53.87, indicating neutral momentum rather than an overbought condition. Traders are watching the 50-day SMA of $51.11 closely; the stock sits just 1.1% below this level, making it a critical threshold for determining whether the current bounce can evolve into a sustained upward trend.

Market Context and Outlook

Despite the short-term gains, the longer-term technical backdrop remains mixed-to-bearish. The 20-day SMA remains below the 50-day SMA, and a death cross formed in January suggests that rallies may encounter overhead supply. Historical context shows significant sentiment swings, with overbought conditions observed in October 2025 and oversold conditions in March. Investors will monitor whether the current momentum can overcome these technical headwinds and establish a new baseline above key resistance levels.